Acoramidis shows early and sustained kidney-protective effects in ATTR-CM patients, improving heart and kidney health.

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), demonstrated early and sustained kidney-protective effects in clinical trials. The drug caused a reversible dip in kidney filtration rate and reduced urinary albumin levels, indicating direct kidney benefits similar to ACE inhibitors and SGLT2 inhibitors. These kidney effects were linked to improved cardiovascular outcomes, including lower risks of death and hospitalization. Acoramidis is approved in the US and Europe and represents a significant advancement in treating ATTR-CM by protecting both heart and kidney functions.